Invesco Ltd. Has $1.22 Million Stock Holdings in Intellia Therapeutics, Inc. $NTLA

Invesco Ltd. boosted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 77.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 171,175 shares of the company's stock after purchasing an additional 74,741 shares during the quarter. Invesco Ltd. owned about 0.17% of Intellia Therapeutics worth $1,217,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the business. Voloridge Investment Management LLC increased its position in Intellia Therapeutics by 226.8% during the fourth quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company's stock worth $17,805,000 after acquiring an additional 1,059,751 shares during the period. Two Sigma Advisers LP grew its position in Intellia Therapeutics by 94.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company's stock worth $23,300,000 after purchasing an additional 970,700 shares during the last quarter. Two Sigma Investments LP increased its holdings in shares of Intellia Therapeutics by 88.1% during the 4th quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company's stock worth $21,498,000 after purchasing an additional 863,363 shares during the period. Vanguard Group Inc. raised its position in shares of Intellia Therapeutics by 5.5% during the first quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company's stock valued at $76,447,000 after buying an additional 561,978 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Intellia Therapeutics by 36.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,976,212 shares of the company's stock valued at $23,042,000 after buying an additional 528,962 shares during the period. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics Trading Down 0.8%

NTLA stock traded down $0.09 during trading on Thursday, hitting $11.62. 2,964,584 shares of the stock traded hands, compared to its average volume of 4,080,177. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -2.48 and a beta of 2.28. Intellia Therapeutics, Inc. has a one year low of $5.90 and a one year high of $23.76. The company has a 50 day simple moving average of $11.40 and a 200 day simple moving average of $9.61.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative net margin of 908.48% and a negative return on equity of 57.48%. The company had revenue of $14.25 million during the quarter, compared to analyst estimates of $12.26 million. During the same quarter last year, the business posted ($1.52) earnings per share. The company's revenue was up 104.3% on a year-over-year basis. As a group, analysts predict that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Intellia Therapeutics news, EVP Edward J. Dulac III sold 7,462 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a total transaction of $104,617.24. Following the sale, the executive vice president owned 106,062 shares of the company's stock, valued at $1,486,989.24. This represents a 6.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William J. Chase acquired 100,000 shares of the stock in a transaction on Wednesday, August 20th. The stock was bought at an average price of $10.03 per share, with a total value of $1,003,000.00. Following the transaction, the director directly owned 134,693 shares in the company, valued at approximately $1,350,970.79. This represents a 288.24% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 12,534 shares of company stock valued at $153,837 over the last ninety days. Insiders own 3.10% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on NTLA shares. Wells Fargo & Company restated an "overweight" rating and issued a $45.00 target price (down from $50.00) on shares of Intellia Therapeutics in a research note on Friday, August 8th. Citigroup dropped their price objective on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Guggenheim reiterated a "buy" rating and set a $14.00 target price on shares of Intellia Therapeutics in a research report on Wednesday, August 13th. Canaccord Genuity Group dropped their price target on shares of Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a research report on Tuesday, June 3rd. Finally, Wedbush restated a "neutral" rating and set a $7.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 16th. Twelve research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $29.05.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.